Can metabolic inflammation lower active thyroid hormone availability without primary thyroid failure?

Central Suppression of the HPT Axis

• Cytokine-Mediated Inhibition: Pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) directly downregulate thyrotropin-releasing hormone (TRH) expression in the paraventricular nucleus.
• Hypothalamic Tanycyte Feedback: Activation of the IKKβ/NF-κB pathway in tanycytes upregulates type 2 deiodinase (D2), generating localized T3 excess. This mimics systemic euthyroid status to the brain, suppressing TRH and TSH.
• Leptin Resistance: Chronic inflammation promotes leptin resistance, blunting the permissive signals required for optimal TRH synthesis.

Peripheral Deiodinase Dysregulation

• Impaired T4-to-T3 Conversion: Inflammatory cytokines downregulate the expression and activity of type 1 (DIO1) and type 2 (DIO2) deiodinases in peripheral tissues, reducing the conversion of thyroxine (T4) to active triiodothyronine (T3).
• Accelerated Inactivation: NF-κB-dependent signaling upregulates type 3 deiodinase (DIO3), which actively degrades T4 into inactive reverse T3 (rT3), and T3 into diiodothyronine (T2).

Non-Thyroidal Illness Syndrome (NTIS)

• Extrathyroidal Pathology: This coordinated downregulation of central signaling and peripheral conversion occurs independently of primary thyroid gland failure. It is clinically recognized as non-thyroidal illness syndrome (NTIS) or euthyroid sick syndrome, serving as an adaptive, allostatic metabolic adjustment during chronic inflammatory stress.

Bottom line

Metabolic xinflammation drives Non-Thyroidal Illness Syndrome by suppressing central HPT-axis signaling and altering peripheral deiodinase activity (downregulating DIO1/D2 and upregulating DIO3), resulting in reduced active T3 without any intrinsic pathology of the thyroid gland.